| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4000128 | Urologic Oncology: Seminars and Original Investigations | 2013 | 8 Pages |
Abstract
Although no PSA responses (primary endpoint) was observed, lapatinib may have biologic activity in men with stage D0 prostate cancer as evidenced by a decrease in PSA slope in this non-randomized study. Additional trials assessing the role of EGFR overexpression and Kras wild type status in prostate cancer should be investigated.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Glenn M.D., Yu-Hui M.S., Jill Pharm. D., Wei M.D., Robert M.D., Michael M.D., Michael M.D., Mark M.D., Glenn J. M.D., George M.D.,